BACKGROUND: Biochemical analyses of mechanisms triggered in platelets (PLTs) upon pathogen inactivation (PI) are crucial to further understand the impact of PI on PLT functionality and, subsequently, quality.
R iboflavin and ultraviolet light (RF/UV) treatment is one of several pathogen inactivation (PI) technologies currently available. 1 These treatments aim to target the replication and/or proliferation mechanism of pathogens and to destroy residual white blood cells (WBCs) to improve the safety of blood components. Although accumulating data demonstrate that RF/UV treatment significantly improves the safety of platelet (PLT) concentrates (PCs), 2 this treatment also negatively impacts PLT efficacy (posttransfusion recovery and survival) and quality, leading to increased PLT activation, acceleration of metabolic activity, and development of apoptosis. 3, 4 Mitochondria (MT) are well known as the cellular powerhouse, generating energy in the form of adenosine triphosphate, while also playing critical roles in multiple cellular activities, such as cell division, differentiation, and apoptosis development in nucleated cells. 5, 6 Although
PLTs are anucleate cell fragments derived by megakaryocytes from marrow, they contain fully functional MT transferred from their progenitors. 7 PLT MT are a key signaling component, modulating several aspects of PLT activation and aggregation, apoptosis development, and PLT life span in vivo. [8] [9] [10] Mitochondrial membrane depolarization occurs in PCs during blood bank storage and further increases upon PI treatment. [11] [12] [13] Recently, we and other groups have demonstrated that apoptotic events including phosphatidylserine (PS) exposure, increased proapoptotic protein expression, and caspase activation are triggered by RF/UV treatment in stored PCs, further supporting the model that apoptosis is involved in development of the PLT storage lesion. 14, 15 However, the detailed biochemical mechanism(s) triggered by RF/UV are still unclear. PLTs can generate reactive oxygen species (ROS), such as O -2 , OH -, and H 2 O 2 , which play critical roles in regulating PLT activity. 16 The PLT mitochondrion is the major source of intracellular ROS generation with hydrogen peroxide (H 2 O 2 ) generated in PLTs activated by thrombin, adenosine 5 0 -diphosphate (ADP), or collagen. 17, 18 Furthermore, the generation of H 2 O 2 triggered by thrombin induces mitochondrial translocation of proapoptotic Bcl-2 family proteins and results in damage to the PLT mitochondrial integrity, release of cytochrome c (cyto c), and loss of PLT mitochondrial membrane potential. 19 In addition, RF/UV treatment of blood components triggers ROS generation resulting in oxidative damage of plasma proteins and mitochondrial DNA (mtDNA). 20, 21 Although antioxidant systems present in cells and PLTs can function as scavengers to inactivate the excess intracellular ROS, high levels of ROS can result in the destruction of macromolecules and lead to cell death. The p38 mitogen-activated protein kinase (p38 or p38 MAPK) is a stress kinase belonging to the mitogenactivated kinase superfamily; it regulates several signaling cascades involved in cell division, differentiation, and apoptosis. 22 In human PLTs, p38 is linked to agoniststimulated PLT activation, as well as the PLT storage lesion. 23, 24 We and others have shown that phosphorylation of p38 is triggered by RF/UV treatment and subsequent blood banking storage. Inhibition of p38 activity before the PI treatment significantly improved the PLT quality and reduced PLT apoptosis development by the decrease of PS exposure, proapoptotic protein expression, and caspase activation. 14, 15, 25 The aim of this study was to evaluate the effects of RF/UV treatment on PLT mitochondrial function and signaling, including the recently discovered release of MT by PLTs, and to determine whether p38 is involved in the modulation of these mechanisms.
MATERIALS AND METHODS

Materials
Common chemicals were purchased from Sigma-Aldrich or Fisher Scientific. SB203580, a p38 MAPK inhibitor, was purchased from Santa Cruz Biotechnology.
Apheresis PC preparation
This study was approved by the research ethics board of Canadian Blood Services and informed consent was obtained from all healthy volunteers before blood donation. Phlebotomy and plateletpheresis were carried out by the NetCAD development laboratory of Canadian Blood Services (Vancouver, Canada) using a Trima Accel (TerumoBCT).
RF/UV treatment and inhibitor study
The SB inhibitor stock solution in dimethyl sulfoxide (DMSO) was diluted in phosphate-buffered saline (PBS) and sterile filtered before spiking. The study design of PCs treated with RF/UV and/or inhibitor is illustrated in Fig. 1 . Double-apheresis PCs were pooled and split into four small illumination bags (provided by TerumoBCT) filled with 59 6 1 mL PC and containing 1186 3 10 9 6 128 3 10 9
PLTs/L. Unit 1 served as an untreated negative control to which 9 mL of saline was added to compensate for the volume of the RF solution in Units 2 to 4. Unit 2 served as a RF/UV-treated positive control to which 9 mL RF (50 mmol/L final concentration) was added. Unit 3 served as an inhibitor vehicle control and contained the amount (0.1%) of the solvent (DMSO) equivalent to that of Unit 4. Unit 4 was spiked under sterile conditions with the p38 inhibitor SB203580 to a final concentration of 10 mmol/L, followed by addition of 9 mL of RF. Units 2, 3, and 4 underwent UV light treatment according to the manufacturer's protocol (Mirasol, TerumoBCT). Samples were collected under sterile conditions on Days 1, 5, and 7 of storage for subsequent analyses.
Subcellular fractionation of PLT lysates
The isolation of subcellular mitochondrial and cytosolic fractions was performed by a mitochondrial isolation kit (Pierce Biotechnology). The protocol was slightly modified compared to the manufacturer's instructions and all buffers used in performing isolation were provided in the kit. Briefly, the PLT samples were washed in 13 CGS buffer (12.9. mmol/L sodium citrate, 33.33 mmol/L glucose, 123.2 mmol/L NaCl, pH 7.0) and resuspended in buffer A to a concentration of 1 3 10 12 /L. PLTs were then broken using a Dounce homogenizer in an ice bath. An equal volume of Buffer C was added, the samples were centrifuged at 700 3 g at 48C for 10 minutes, and then the supernatant was transferred to a new tube and centrifuged again at 12,000 3 g at 48C for 15 minutes. The resulting supernatant represented the cytosolic fraction, and the pellet contained the enriched mitochondrial fraction.
Determination of PLT mitochondrial transmembrane potential
The PLT mitochondrial potential (DW m ) was monitored using a cell-permeable cationic, red-orange fluorescent dye tetramethylrhodamine ethyl ester (Life Technologies). The PLT samples were diluted to a concentration of 200 3 10 9 /L with Tyrode's buffer (137 mmol/L NaCl,
mmol/L glucose, pH 7.4) containing 0.35% bovine serum albumin (BSA). Tetramethylrhodamine ethyl ester was added to the diluted PLTs to a final concentration of 100 nmol/L in a total volume of 50 mL and incubated at room temperature in dark for 20 minutes. After incubation, 950 mL of Tyrode's buffer with 0.35% BSA was added and samples were analyzed on a flow cytometer (FACSCanto II, BD Biosciences). In parallel, a freshly prepared PLT-rich plasma sample was used to set a control gate.
Intracellular ROS generation in apheresis PCs
The generation of H 2 O 2 , a member of the ROS, was analyzed by a flow cytometry assay using the cell-permeable fluorescent reagent 2 0 ,7 0 -dichlorofluorescein diacetate (Sigma-Aldrich). The PLT samples were diluted using PBS buffer to a concentration of 200 3 10 9 PLTs/L followed by the addition of the 2 0 ,7 0 -dichlorofluorescein diacetate to a final concentration of 10 mmol/L in a total volume of 100 mL. The prepared mix was incubated in dark at 378C for 30 minutes. Before the flow cytometric analysis, the sample was diluted 10-fold with filtered PBS buffer. Control gates were set using a freshly prepared PLT-rich plasma sample.
Detection of the free microvesicles, free MT, and microvesicles encapsulating MT
Release of free microvesicles (MVs), free MT, and MVs containing MT (MVs/MT) from PLTs was analyzed by adapting the protocol of Boudreau and colleagues. 26 This approach uses a specific gating strategy that can distinguish MVs with a size range of 100 to 1000 nm diameter using a submicron particle size reference kit (Life Technologies). PLT-poor plasma (PPP) was collected by centrifugation of PCs twice at 1000 3 g at room temperature and then diluted 10-fold with PBS buffer containing 0.25% BSA and 200 mmol/L NaCl. Ten microliters of the diluted PPP was incubated with 5 mL of CD41-PC5 (Beckman Coulter, Inc.) to label glycoprotein IIb and a final concentration of 100 nmol/L MitoTracker Green FM dye (Life Technologies) to label MT in a total volume of 50 mL. After incubation for 40 minutes at room temperature in the dark, 10,000 polystyrene counting beads (Polysciences, Inc.) and PBS buffer were added to a final volume of 1 mL before analyzing by flow cytometer (FACSCanto II, BD Biosciences). One thousand counting beads were collected for each sample and the respective counts of MVs, MT, or MT/MVs were determined.
Extracellular mtDNA in PCs
The effect of RF/UV treatment on the release of mtDNA by PLTs during storage was determined by quantitative polymerase chain reaction (qPCR) following the protocol published by Lauring and colleagues. 27 Briefly, PPP collected by a two consecutive centrifugation steps (200 3 g, 10 min; then 2500 3 g, 20 min) at room temperature was used for isolation of total DNA. The extraction of DNA was performed using a DNA extraction kit (QIAamp 96 DNA Blood Mini kits, Qiagen, Inc.). Primers targeting mitochondrial cytochrome oxidase III subunit c, were used to amplify a 103 bp fragment. The qPCR was performed in a 96-well format on a sequence detection system (LightCycler 480 II, Roche Applied Science).
Immunoblot analysis
For protein analyses, the isolated enriched mitochondrial and cytosolic fractions were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and blotted onto nitrocellulose membranes (Bio-Rad). Membranes were probed with primary antibodies against Bax, Bid, cyto c, cyto c oxidase subunit IV, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology, Inc.) followed by their respective secondary antibodies (LI-COR). Protein band intensities were quantified by densitometry using imaging analysis software on a bioimaging system (Odyssey, LI-COR).
Statistical analysis
All variables measured are reported as means 6 1 standard deviation. Statistical analyses were performed using twoway analysis of variance with repeated measures, and post hoc test analyses were conducted using Bonferroni posttest using computer software (GraphPad Prism 5, GraphPad Software, Inc.). A p value of less than 0.05 was considered significant.
RESULTS
Protein expression levels in subcellular factions of PLTs after RF/UV light treatment
The level of cyto c in the cytosolic and MT-enriched fractions was determined by immunoblot analysis. The release of cyto c from the MT into the cytosol was increased during storage and significantly enhanced by RF/UV treatment in comparison to the untreated control on Day 7 of storage (p < 0.01; Fig. 2A ). In the presence of the SB inhibitor the release activity triggered by PI treatment was significantly reduced compared to vehicle control on Day 7 (p < 0.05). The cyto c release was verified by immunoblot analysis of MT-enriched fractions (Fig. 2B) .
Inverse to the results seen in the cytosolic fraction, the level of cyto c in MT-enriched fraction was decreased in the RF/UV-treated samples compared to untreated control on Days 5 and 7 (p < 0.01), and the decreasing trend was inhibited by the SB inhibitor compared to vehicle control on Day 7 (p < 0.05).
The translocation of the proapoptotic Bcl-2 family proteins has been linked to damage of mitochondrial outer membrane leading to the cyto c release. To investigate the effect of PI treatment on the translocation activities in PCs during storage, the levels of Bcl-2 proteins Bax and Bid were analyzed in MT-enriched fractions by immunoblot. As shown in Figs. 2C and 2D, the levels of the Bax and Bid in the MT-enriched fractions were each increased in RF/UV-treated samples compared to the untreated control on Day 7 (p < 0.05) and significantly decreased by the SB203580 inhibitor (p < 0.05).
The loss of DW m and ROS generation in PLTs triggered by RF/UV treatment
To verify the data on mitochondrial protein translocations and cyto c release obtained by immunoblot analyses, the PLT mitochondrial DW m was monitored by a flow assay throughout 7 days of storage. As shown in Fig. 3A , the loss of DW m was greater in RF/UV-treated PCs compared to the control on Day 7. In the presence of SB inhibitor, the loss of DW m triggered by the treatment was significantly less on Day 7 but as this difference is quite small this result might not be biologically relevant.
It has been suggested that the production of ROS might contribute to damage to mitochondrial membrane integrity resulting in apoptosis development in mammalian cells. 28 In this study, the intracellular ROS generation in PCs triggered by RF/UV treatment was determined by measuring H 2 O 2 on Days 1, 5, and 7 of storage. Figure 3B shows that the production of ROS was significantly increased in the treated samples compared to the untreated control on Days 5 and 7 (p < 0.01). The SB inhibitor reduced the ROS generation compared to the vehicle control on Day 7.
Free MVs, MVs/MT, and free MT release by PLTs upon RF/UV treatment
The extracellular levels of free MPs, MT, and MVs/MT were monitored by flow assays on Days 1, 5, and 7 of storage. The release of the free MVs (Fig. 4A ) and MVs/MT (Fig. 4B) was increased in the RF/UV-treated units compared to the untreated control by Day 5 (p < 0.01). Compared to the vehicle (DMSO) control, the presence of the SB inhibitor reduced MV release by Day 7 (p < 0.01) and the extracellular MVs/MT by Day 5 (p < 0.01). As shown in Fig. 4C , free MT release was increased by RF/UV treatment compared to the untreated control on Day 7 (p < 0.05), but there was no significant change with addition of the SB inhibitor before the RF/UV treatment.
Extracellular mtDNA level in PCs after RF/UV treatment
As shown in Fig. 5 , the extracellular level of mtDNA displayed an increase in PCs during storage. However, there were no significant changes in either RF/UV-treated units compared to the untreated control or SB inhibitor-treated units compared to the vehicle control during storage.
DISCUSSION
Despite the improved safety of PI-treated blood components, the undesired impact of PI treatment on PLT quality and function remains a concern. Recent proteomic studies have identified several potential proteins that could be applied as markers to monitor PLT quality after PI treatment and further fine-tune the technology. Stemming from these proteomic results, mechanistic models need to be created and tested to reveal underlying molecular events triggered by the PI process. 1 Previously, we and others have demonstrated that inhibition of the stress kinase p38 improves PLT in vitro quality with or without RF/UV treatment during storage, showing a deceleration of apoptosis development. 15, 25, 29 Here we provide further insights into the mechanism of the impact of RF/UV treatment on PLT mitochondrial function and demonstrate that some of these activities are also modulated by p38 MAPK. Accumulating evidence demonstrates that PI-treated PLTs share highly similar behaviors with PLTs stimulated by physiologic activators, including PLT activation, degranulation, and development of apoptosis, leading to the conclusion that these processes have the same signaling mechanism. Lopez and coworkers 30 reported that thrombin induces translocation of Bax, Bak, and active Bid to MT resulting in cyto c release and subsequent loss The generation of ROS can be beneficial or harmful to cells and tissues. 17 Under physiologic conditions, low levels of ROS act as second messengers in regulating cell activity, while excess ROS can induce oxidative modification of intracellular proteins leading to cell apoptosis. 31 PLTs contain fully functional MT, which are the main intracellular source of ROS generation, for example, H 2 O 2 , which is produced by the respiratory chain complexes. Mitochondrion-derived ROS generation has been implicated in signaling of the PLT apoptosis that can lead to hyperthermia-induced thrombocytopenia in patients receiving cancer treatments. 32 Generation of H 2 O 2 in thrombin-or ADP-stimulated PLTs has been demonstrated to trigger the loss of the mitochondrial DW m and lead to apoptotic events. 19, 33 Previously, several studies have reported that RF and UV light can trigger intracellular generation of ROS in PLTs modulating signaling pathways and causing oxidative damage of macromolecules. 20, 21, 34 In this study, we also show that the RF/UV treatment generated intracellular H 2 O 2 in apheresis PCs throughout storage, which might contribute to the depolarization of the DW m further contributing to apoptosis development.
The p38 MAPK is well known to modulate signaling pathways leading to apoptosis development in nucleated cells. In human PLTs, it is also phosphorylated in a timeor dose-dependent manner by PLT agonists. 23 Canault and colleagues 24 reported that p38 activation is involved in PLT storage lesion, and inhibition of p38 activity significantly improves PLT transfusion outcome in a mouse model. Our previous studies have shown that RF/UV treatment triggers immediate phosphorylation of p38 in apheresis PCs with an increasing trend during storage. 15, 25 Addition of the p38 inhibitor SB203580 before RF/UV treatment results in significantly improved ex vivo PLT quality, demonstrated by the down regulation of PLT activation, PS exposure, and apoptosis development. 15, 25 In this study, we further show that this compound inhibits the mitochondrial translocation of Bax and Bid in RF/UVtreated PLTs and protects mitochondrial integrity by decreasing cyto c release and loss of DW m , effects that might explain the reduced PS exposure and caspase activities we previously reported when this inhibitor was used. 25 Although intensive investigations have reported that p38 signaling plays a critical role in modulating cell activities by either promoting apoptosis or enhancing cell survival, 22 its function in PLT apoptosis remains unclear.
Rukoyatkina and coworkers 35 showed that p38 is involved in PLT apoptosis using a BH3 mimic compound ABT-737. p38 signaling is also involved in PLT apoptosis triggered by staurosporine, a microbial alkaloid, showing that inhibition of p38 decreases the loss of DW m and PS exposure.
36
A study using a virus-transformed B-cell model also concluded that ROS-mediated p38 signaling is involved in apoptosis development. 10 Our data presented here show that p38 might regulate the intrinsic apoptotic pathway in PLT through modulation of intracellular ROS generation and translocation of proapoptotic proteins to PLT mitochondrial membrane. The shedding of PLT MVs is increased in PCs upon PI treatment and subsequent storage. [37] [38] [39] Although the function of PLT MVs in vivo is still unclear, the large amount of MVs in a storage bag remains a concern with respect to transfusion safety. Recently, Boudreau and colleagues 26 reported that PLTs can shed not only MVs but also free MT and MVs/MT during storage, which can act as damage-associated molecular profiles. 40 Further investigations demonstrated that release of MT functions to promote bacterial infection and inflammation. 26 Here, we
showed that RF/UV treatment triggers the release of the free MVs, free MT, and MVs/MT in apheresis PCs during storage. Moreover, the SB inhibitor reduced the release of free and MT-containing MVs during storage. Apoptosis development is linked to MVs release by PLTs, 41, 42 suggesting that p38 signaling might be involved in the modulation of apoptosis development and subsequent MVs release triggered by RF/UV treatment. mtDNA is a highly potent inflammatory mediator when present extracellularly 26, 43 and may cause transfusion-related side effects. 44 We observed that the level of extracellular mtDNA did not significantly increase in apheresis PCs upon the RF/UV treatment and during storage. Recently, Cognasse and coworkers 45 reported that extracellular mtDNA is consistently increased in PCs from Day 1 to Day 4 but decreased on Day 5 of storage. Applying a qPCR method using a pair of primers for long-length amplicons (>1800 bp) but not for short amplicons (200 bp), Bakkour and colleagues 46 have reported that RF/UV treatment of pooled PCs or plasma significantly damages the mtDNA and can be applied as a quality control measure to demonstrate efficacy of PI. Although the flow cytometry results showed that the extracellular MT (free and MVs/MT) are elevated in RF/UV-treated PCs compared to untreated controls during storage, the extracellular mtDNA level did not significantly increase in treated units. It may be that RF/UV treatment does not affect the free mtDNA release during storage or the mtDNA release caused by this primer does not reflect the total extracellular mtDNA level known that the RF/UV treatment targets the DNA sequence.
Propelled by the results presented here, we can modify our earlier model 15 to also include a role for p38 MAPK in regulating mitochondrial function. Activation of this kinase by RF/UV treatment seems to propel mitochondrial deregulation, which contributes to the development of apoptosis. Inhibition of this kinase reduces this process as demonstrated by decelerated PLT activation and metabolism 15 and caspase-dependent apoptosis. 25 As the previous study in mice demonstrated improved PLT survival after transfusion of PLTs treated with the p38 inhibitor, 24 further studies are necessary to understand the correlation of PLT in vitro quality and in vivo survival in the PI setting. Deceleration of PLT deterioration upon PI treatment while maintaining PI capacity to inactivate pathogens and WBCs is the ultimate goal of these research studies.
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